Clinical trials

NN7535-7807 A global phase III, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease

A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial)

The purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapy (FOLFIRI, mFOLFOX6) to participants with metastatic CRC that lack mutations in genes called KRAS/NRAS and BRAF. Cetuximab, FOLFIRI and mFOLFOX6 are already used to treat participants with this type of cancer.

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)

MM1YA-S01, "A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A MyeloMATCH Clinical Trial"

This study is being done to answer the following question:
How do two new types of blood screening tests for cancer, called multi-cancer detection (MCD) tests work for people who are eligible to be screened for cancer?
This study is the first part of a larger plan to evaluate how well these MCD tests work across different communities in the United States, for detecting a number of different cancers.

This research study is to evaluate the safety and efficacy of the investigational study drug, ATR04-484, as a possible treatment for dermal toxicity associated with EGFRi treatment. If you have a moderate to severe skin reaction that your doctor recognizes is due to the EGFRi medication you receive for cancer, you may be able to participate in this study.

This study involves skin cancer treatment for patients who have had either a kidney, liver, heart and/or a lung or other solid organ transplant or a hematopoietic cell transplant. 


This trial is being done to look at the effects of RP1 in kidney, liver, heart, lung, solid organ and hematopoietic cell transplant recipients with advanced skin cancer. RP1 is a herpes simplex virus (a microscopic life form commonly known as the "cold sore virus") that has been genetically changed to allow the virus to grow and destroy cancer cells, spread selectively from tumor cell to tumor cell, and activate the immune system to attack cancer cells. RP1 has also been genetically changed so that it cannot divide efficiently in normal cells.

The purpose of this study is to find out if patients receiving endocrine therapy before the lumpectomy (and to better understand how they tolerate the drug(s)) would result in fewer patients receiving breast cancer surgery alone (no radiation or endocrine therapy) and fewer patients receiving breast cancer surgery plus radiation and endocrine therapy.

This study is being done to answer the following question:  

Can the addition of a high dose of radiation therapy extend life or improve quality of life?  

We are doing this study because we want to find out if this approach is better or worse than the usual approach for locally advanced pancreatic cancer.  The usual approach is defined as care most people get for locally advanced pancreatic cancer.